-
August 2, 2024
-
August 2, 2024
-
August 2, 2024
-
October 4, 2024
Eisai Announces Status and Completion of Acquisition of Own Shares
-
October 2, 2024
EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN SAUDI ARABIA
-
October 1, 2024
-
September 24, 2024
ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) APPROVED IN JAPAN FOR AMYOTROPHIC LATERAL SCLEROSIS
-
September 24, 2024
Latest Financial Reports
Consolidated Financial Report for First Quarter Financial Results for the Fiscal Year Ending March 31, 2025
Financial Information
Latest Presentations
- First Quarter Financial Results for FY2024 (August 2, 2024)
- First Quarter Financial Results for FY2024 (Webcast) (August 2, 2024)
- Presentation at The Alzheimer’s Association International Conference (AAIC) 2024: Perspectives Session:
Does the Current Evidence Base Support Lecanemab Continued Dosing for Early Alzheimer’s Disease? - Presentation at The Alzheimer’s Association International Conference (AAIC) 2024: Featured Research Session:
Beyond Amyloid Removal with Lecanemab Treatment: Update on Long-Term Imaging and Fluid Biomarkers
-
Management Policy
-
Value Creation Report (Former Integrated Report) / Human Capital Report
-
Financial Data
Electronic Public Notice
No corporate bonds have been issued at present.